BMS And Prothena’s Expanded Deal Shows Growing Confidence In Targeting Tau
But First Clinical Benefits Yet To Be Seen
After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.
